JP2023536636A - 腫瘍の分類及び応答性の予測 - Google Patents

腫瘍の分類及び応答性の予測 Download PDF

Info

Publication number
JP2023536636A
JP2023536636A JP2023507701A JP2023507701A JP2023536636A JP 2023536636 A JP2023536636 A JP 2023536636A JP 2023507701 A JP2023507701 A JP 2023507701A JP 2023507701 A JP2023507701 A JP 2023507701A JP 2023536636 A JP2023536636 A JP 2023536636A
Authority
JP
Japan
Prior art keywords
therapy
group
immunomodulatory
gene
responsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536636A5 (https=
Inventor
スコット サイツ，ロバート
ハウト，ディビッド
ジョン ニールセン，タイラー
ロイド シュバイツァー，ブロック
ゼット リング，ブライアン
ティ ロス，ダグラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Molecular Diagnostics Inc
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of JP2023536636A publication Critical patent/JP2023536636A/ja
Publication of JP2023536636A5 publication Critical patent/JP2023536636A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
JP2023507701A 2020-08-03 2021-08-02 腫瘍の分類及び応答性の予測 Pending JP2023536636A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060321P 2020-08-03 2020-08-03
US63/060,321 2020-08-03
US202063121837P 2020-12-04 2020-12-04
US63/121,837 2020-12-04
US202163173180P 2021-04-09 2021-04-09
US63/173,180 2021-04-09
PCT/US2021/044240 WO2022031630A1 (en) 2020-08-03 2021-08-02 Classifying tumors and predicting responsiveness

Publications (2)

Publication Number Publication Date
JP2023536636A true JP2023536636A (ja) 2023-08-28
JP2023536636A5 JP2023536636A5 (https=) 2024-08-13

Family

ID=80118483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507701A Pending JP2023536636A (ja) 2020-08-03 2021-08-02 腫瘍の分類及び応答性の予測

Country Status (8)

Country Link
US (1) US20230296584A1 (https=)
EP (1) EP4188330A4 (https=)
JP (1) JP2023536636A (https=)
KR (1) KR20230058410A (https=)
CN (1) CN116322639A (https=)
AU (1) AU2021322092A1 (https=)
CA (1) CA3188358A1 (https=)
WO (1) WO2022031630A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
CN115436636A (zh) * 2022-11-08 2022-12-06 济南市中心医院 连接粘附分子样蛋白jaml在结直肠癌中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524934A (ja) * 2011-07-29 2014-09-25 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080381A1 (en) * 2012-11-26 2014-05-30 Ecole Polytechnique Federale De Lausanne (Epfl) Colorectal cancer classification with differential prognosis and personalized therapeutic responses
GB201512869D0 (en) * 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2018132916A1 (en) * 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3727368A4 (en) * 2017-12-19 2021-10-20 Abraxis BioScience, LLC METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY
EP3788369A1 (en) * 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN110927389B (zh) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524934A (ja) * 2011-07-29 2014-09-25 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置

Also Published As

Publication number Publication date
EP4188330A1 (en) 2023-06-07
CA3188358A1 (en) 2022-02-10
KR20230058410A (ko) 2023-05-03
US20230296584A1 (en) 2023-09-21
AU2021322092A1 (en) 2023-03-02
EP4188330A4 (en) 2024-09-04
WO2022031630A1 (en) 2022-02-10
CN116322639A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
US12152075B2 (en) Treatment of renal cell carcinoma
JP7197556B2 (ja) がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法
JP2018505658A (ja) Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
KR20190016025A (ko) 고형 암을 갖는 환자의 분류 방법
JP2026049725A (ja) 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム
JP2024511166A (ja) 癌の標的療法
EP4127244A2 (en) Biomarker panels for stratification of response to immune checkpoint blockade in cancer
JP2019529437A (ja) 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法
JP2023536636A (ja) 腫瘍の分類及び応答性の予測
EP3908678A1 (en) System and methods for monitoring adoptive cell therapy clonality and persistence
US20240084391A1 (en) Diagnostic Methods and Methods of Treatment of Ovarian Cancer
WO2023150194A2 (en) Classifying tumors and predicting responsiveness
JP7772700B2 (ja) 神経膠芽腫を処置するための方法
JP2024509360A (ja) がんにおける方法およびバイオマーカー
US12462941B2 (en) Pan-cancer tumor microenvironment classification based on immune escape mechanisms and immune infiltration
US20240336975A1 (en) Biomarkers Predicting Response of Breast Cancer to Immunotherapy
HK40095165A (zh) 肿瘤分类和反应性预测
WO2024025923A1 (en) Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockade therapies and combinations thereof
WO2019178214A1 (en) Methods and compositions related to methylation and recurrence in gastric cancer patients
Zavacky Investigating the heterogeneity of tumour-associated macrophages in renal cell carcinoma milieu
JP2025076406A (ja) がん免疫療法に対する応答を予測するための方法、システム及び組成物
Jørgensen et al. E‐POSTERS
HK40102168A (zh) 卵巢癌的诊断方法和治疗方法
CN117321225A (zh) 癌症的靶向疗法
엄혜현 Analysis of genetic heterogeneity of tumor-infiltrating immune cells in human cancer by single-cell RNA sequencing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260310